Bank of New York Mellon
KPRX icon

Bank of New York Mellon’s Kiora Pharmaceuticals KPRX Stock Holding History

Bank of New York Mellon’s Portfolio KPRX Stock Details KPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-5
Closed -$11K – 4264
2018
Q1 		$11K Buy
+5
New +$21.6K ﹤0.01% 4291

Other funds holding KPRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon's KPRX Position: Q2 2018 in Review

Bank of New York Mellon sold out of Kiora Pharmaceuticals (KPRX) in Q2 2018, closing a stake of 5 shares — an estimated $11K sold.

Bank of New York Mellon first reported a position in KPRX in Q1 2018 and held it in 1 quarter. The position peaked at $11K in Q1 2018. 17 funds tracked by Wall St. Rank hold KPRX as of Q2 2018.

  • Bank of New York Mellon reported no remaining Kiora Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Bank of New York Mellon sold 5 Kiora Pharmaceuticals shares in Q2 2018, an estimated $11K.
  • Bank of New York Mellon first reported a position in Kiora Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Bank of New York Mellon's Kiora Pharmaceuticals position peaked at $11K in Q1 2018.
  • 17 funds tracked by Wall St. Rank held Kiora Pharmaceuticals as of Q2 2018.

Based on Bank of New York Mellon's 13F filing for Q2 2018, filed 6 Aug 2018.